Wong R, Yuan LY. Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both. World J Hepatol 2024; 16(6): 871-877 [PMID: 38948439 DOI: 10.4254/wjh.v16.i6.871]
Corresponding Author of This Article
Rochelle Wong, MD, Doctor, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, 1510 San Pablo St. HC1-Suite 200, Los Angeles, CA 90033, United States. rochellewong15@gmail.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Hepatol. Jun 27, 2024; 16(6): 871-877 Published online Jun 27, 2024. doi: 10.4254/wjh.v16.i6.871
Sarcopenia and metabolic dysfunction associated steatotic liver disease: Time to address both
Rochelle Wong, Li-Yun Yuan
Rochelle Wong, Li-Yun Yuan, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, Los Angeles, CA 90033, United States
Author contributions: Wong R performed the literature review and wrote the manuscript; Yuan LY reviewed and revised the manuscript; and all authors have read and approved of the final manuscript.
Conflict-of-interest statement: The authors have no conflicts of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Rochelle Wong, MD, Doctor, Division of Gastrointestinal and Liver Diseases, Keck School of Medicine of University of Southern California, 1510 San Pablo St. HC1-Suite 200, Los Angeles, CA 90033, United States. rochellewong15@gmail.com
Received: February 17, 2024 Revised: April 23, 2024 Accepted: April 29, 2024 Published online: June 27, 2024 Processing time: 123 Days and 19.1 Hours
Core Tip
Core Tip: Sarcopenia and metabolic dysfunction associated steatotic liver disease (MASLD) share a bidirectional relationship along the liver-muscle axis. With similar pathophysiology and shared risk factors, MASLD is a risk factor for sarcopenia, and vice versa. Early identification and adequate diagnosis are important. However, lack of consensus definition made it difficult to research outcomes. With the recently updated consensus definition for MASLD, researchers may now better identify proper cohorts for study. Consensus on gold standard techniques and muscle mass cutoffs to define sarcopenia are still needed. Future research may identify potential therapeutic targets along the shared liver-muscle axis that would improve outcomes for both sarcopenia and MASLD.
